A 28-year-old woman with biopsy-proven SLE presents with a 2-week history of fever, arthralgia, and a new malar rash. Laboratory investigations show ANA 1:1280 (homogeneous), anti-dsDNA antibodies 420 IU/mL (normal <70), C3 28 mg/dL (normal 80–160), and C4 12 mg/dL (normal 15–45). Which of the following is NOT typically associated with active SLE?

Explanation

## Complement and Immune Complex Activation in SLE **Key Point:** Active SLE is characterized by complement consumption (hypocomplementemia) and circulating immune complex deposition, NOT by anti-histone antibodies, which are a hallmark of drug-induced lupus (DIL). ### Serological Markers of Active SLE | Finding | Association with Active SLE | Mechanism | |---------|------------------------------|----------| | Anti-dsDNA antibodies | Yes, strong correlation | Directly pathogenic; deposit in glomeruli | | Low C3, C4 | Yes, indicates active disease | Complement consumption by IC deposition | | Elevated C3d, circulating IC | Yes | Marker of immune complex-mediated injury | | Anti-histone antibodies | No (DIL marker) | Characteristic of drug-induced lupus, not idiopathic SLE | | ANA (homogeneous) | Yes | Present in >95% of SLE | **High-Yield:** Anti-histone antibodies are **NOT** a feature of active idiopathic SLE. They are the defining serological marker of **drug-induced lupus (DIL)**, which occurs with drugs like hydralazine, procainamide, isoniazid, and quinidine. Anti-histone positivity in a patient with SLE-like features should prompt a medication history. ### Why Hypocomplementemia Matters in SLE 1. **C3 and C4 consumption** occurs when immune complexes form and activate the classical complement pathway. 2. **C3d** (a breakdown product) accumulates in serum and is a sensitive marker of complement activation. 3. **Low complement levels** correlate with lupus nephritis activity and systemic disease flares. 4. **Normal or elevated complement** in a patient with SLE-like features suggests alternative diagnoses (e.g., ANA-negative lupus variants, other connective tissue diseases). **Clinical Pearl:** A patient with SLE, fever, rash, and hypocomplementemia + elevated anti-dsDNA is in a **disease flare** and at high risk for lupus nephritis. Complement levels should be monitored serially; rising C3/C4 suggests disease remission. **Mnemonic — "DISH" for Drug-Induced SLE features:** - **D**rug exposure (hydralazine, procainamide, etc.) - **I**ncreased anti-histone antibodies - **S**erosis (pleuritis, pericarditis common) - **H**ealth improves after drug withdrawal [cite:Harrison 21e Ch 297]